adverse drug reactions at national level, as recommended in New Drug Policy;

(b) by when data on adverse drug-reactions on Indian population would be generated, for cautioning practising physicians and people at large;

(c) whether Government propose to introduce package-insert of formulations for consumers; and

(d) if so, what are the details thereof?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) and (b) Ministry of Health and Family Welfare has submitted a Scheme for monitoring ADR at the national level in the Seventh Five year Plan which is being examined in consultation with the Ministry of Finance. Once the scheme is approved and necessary facilities are granted, Ministry of Health and Family Welfare would collect data on ADR at the national level and disseminate such data to the practising physicians, concerned association and consumers at large.

(c) There is no immediate proposal to introduce package-insert of ethical formulations for consumers.

(d) in view of (c) above, does not arise.

Inclusion of drugs in category I

142. DR. (SHRIMATI) SAROJINI MAHISHI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that as per the measures announced in December, 1986, all drugs required for National Health Programme be included in category I of DFCO, 1987;

(b) whether it is also a fact that is no where indicated that only those drugs would be included which have exclusive use for diseases under National Health Programme;

(c) if so, what are the names of drugs which have been excluded on the ground that those are not exclusively used for National Health Programmes, though significantly used;

(d) whether it is a fact that such criterion has not been rigidly followed and certain drugs have been recommended under this situation; and

(e) if so, what are the names of those drugs and reasons therefor?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) to (c) Although recommendations were sought from Ministry of Health for drugs required under various National Health Programmes, drugs for 6 National programmes have been enlisted under Category I by Department of Chemicals as per criteria evolved by them.

(d) and (e) Department of Chemicals is engaged in examination of various suggestions received on categorisation of drugs.

Use of Paracetamol and Quinine under National Malaria Eradication Programme

143. DR. (SHRIMATI) SAROJINI MAHISHI:
SHRI RAJNI RANJAN SAHU:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to refer to the answer to Unstarred Question 3406 given in the Rajya Sabha on the 9th December, 1987 and state:

(a) what is the percentage use of Paracetamol and Quinine in National Malaria Eradication Programme;

(b) whether it is a fact that the use of these products is 0 per cent to 2 per cent for this programme;

(c) what is the percentage use of Vitamin A in control of blindness

programme and Mother and Child Health Programme;

(d) what is the percentage of use of Folic Acid, Ferrous salts and Calcium salts under National Family Health Programme they have not been included vague; and

(e) on what basis Quinine Hcl and Paracetamol were recommended for inclusion under category I and Vitamin A, Folic Acid, Ferrous salts and Calcium salts were excluded?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) to (d) A statement showing the quantities procured along with the costs during 1987-88 is annexed. (*See* below).

(e) Drugs for the Mother and Child Programme are being evaluated for price control recommendations under category I to the Department of Chemicals.

Paracetamol has been recommended for exclusion from Category I drugs.

Statement

Quantities of drugs procured under National programmes of NMEP and MCH :—

Malaria Control Programme :

Drug	Quantity	Cost
1. Paracetamol	25 million tabs.	Rs. 13.64 lakhs
2. Chloroquin	210 ,,	Rs. 306.61 lakhs
3. Amodiaquin	20 ,,	Rs. 24.93 lakhs
4. Primaquin	130 ,,	Rs. 18.09 lakhs
		Rs. 363.27 lakhs

NOTE :—Quinine injection and combination drugs are not procured under NMEP programme.

MCH Programme :

Drug	Quantity	Cost
1. Iron and Folic Acid (Large)	224 crore tabs	Rs. 234.00 lakhs
2. Iron and Folic Acid (Small)	216 crore tabs	Rs. 97.00 lakhs
3. Liquid Iron (100 ml)	23 lakh bottles	Rs. 65.54 lakhs
4. Vitamin 'A' solution (100 ml)	9.7 lakh bottles	Rs. 2.03 lakhs
		Rs. 398.57 lakhs